SonoMedica, Inc. is an early stage company which has developed inexpensive, yet powerful noninvasive technology to assist doctors in early diagnosis of cardiovascular diseases, through sophisticated analysis of heart sounds. Initially we have focused on the early detection of coronary artery disease (the single largest health problem in the US for people over 40). Successful clinical engineering trials have been completed at Johns Hopkins (with Dr. Jeffery Brinker as principal investigator) and Walter Reed. On the basis of these early successes, we are confident that the results of an independent multicenter clinical trial begun in early 2008 will demonstrate that SonoMedica has the least expensive, most effective noninvasive tool for the early detection of coronary artery disease. This single application addresses a market which has the potential for annual revenues in the billions of dollars. As exciting as this market is, there are more applications of the technology in the areas of congestive heart failure, arrhythmias, the peripheral vascular system, and sudden cardiac death which can extend the technology for years to come.

The company’s technology represents the fusion of well known medical science with advanced signal detection and analysis tools and expertise developed in the national security community. The company received a second 510-K clearance from the FDA late in the first quarter of 2003, and has a robust and growing portfolio of intellectual property. Approximately $ 6 million in funding has been raised in the past five years. With adequate financing, SonoMedica is poised to become one of the most exciting medical technology companies of the decade.